Looking Under the Surface in Pediatric Atopic DermatitisCollaborative Care for Better Patient Outcomes
Atopic Dermatitis Overview and Pathogenesis
Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis.
Kong HH, et al. Genome Res. 2012;22(5):850-859.
Paternoster L, et al. J Allergy Clin Immunol. 2018:141(3):964-971.
Peng W, Novak N. Clin Exp Allergy. 2015;45(3):566-574.
Patient Burden and Comorbidities
Chamlin SL, et at. Arch Pediatr Adolesc Med. 2005;159(8):745-750.
Mitchell AE. Psychol Res Behav Manag. 2018;11:289-298.
Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis.
Simpson EL, et al. JAMA Dermatol. 2018;154(8):903-912.
Yaghmaie P, et al. J Allergy Clin Immunol. 2013;131(2):428-433.
Management of Atopic Dermatitis
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.
Boguniewicz M, et al. Ann Allergy Asthma Immunol. 2018;120(1):10-22.
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.
Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.
Eichenfield LF, et al. Pediatrics. 2015;136(3):554-565.
Horimukai K, et al. J Allergy Clin Immunol. 2014;134(4):824-830e6.
Huang JT, et al. Pediatrics. 2009;123(5):e808-e814.
Ruzicka T, et al. N Engl J Med. 2017;376(9):826-835.
When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.
Simpson EL, et al. J Am Acad Dermatol. 2017;77(4):623-633.
Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.
Clinical Insights Into Atopic Dermatitis Pathogenesis
This short video discusses the pathophysiology of atopic dermatitis, illustrating how it is a disease of both barrier dysfunction and Th2-driven inflammation. Among Th2 cytokines, IL-4 and IL-13 have demonstrated a key role in AD pathogenesis, which has led to the development of a human monoclonal antibody against IL-4Rα for the treatment of moderate-to-severe disease.
Collaborative Care for Better Patient Outcomes
Pathophysiology to the Management of Moderate-to-Severe Disease
New Strategies to Target Remission and Individualize Comprehensive Care
Targeting Immune Dysregulation and Delivering Comprehensive Care
Looking Beyond Barriers to Optimize Therapy
Debates and Discussions About Pustular Disease Subtypes
Digging Deep on Shared Decision-Making
Pathophysiology, Multimodal Management, and Shared Clinical Decision Making
A Case-Based Update